Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Hendi Pharmaceuticals (301211) main capital net sold 5.2589 million yuan on March 16
Securities Star News: As of the close on March 16, 2026, Hendi Pharmaceutical (301211) closed at 12.31 yuan, up 0.33%, with a turnover rate of 0.63%, trading volume of 26,200 lots, and a transaction amount of 32.2143 million yuan.
Regarding capital flow data on March 16, main funds net outflow was 5.2589 million yuan, accounting for 16.32% of total transaction volume; retail funds net inflow was 387,400 yuan, accounting for 1.2%; retail investors’ net inflow was 4.8715 million yuan, accounting for 15.12%.
Hendi Pharmaceutical’s Q3 2025 report shows that the company’s main business revenue for the first three quarters was 319 million yuan, a decrease of 4.52% year-on-year; net profit attributable to the parent was 20.9334 million yuan, down 71.96% year-on-year; net profit after deducting non-recurring gains and losses was 543,800 yuan, down 99.14% year-on-year; in Q3 2025, the company’s single-quarter main business revenue was 84.1284 million yuan, down 8.68% year-on-year; net profit attributable to the parent was 2.3863 million yuan, down 61.3% year-on-year; non-recurring net profit was -3.8723 million yuan, down 156.27% year-on-year; debt ratio was 5.92%; investment income was 4.7152 million yuan; financial expenses were -8.1472 million yuan; gross profit margin was 20.53%. Hendi Pharmaceutical (301211) main business: mainly engaged in the research, development, production, and sales of chemical raw materials (including intermediates) and formulations, and can provide contract R&D and manufacturing services (CDMO) based on customer needs.
Capital flow terminology explanation: Refers to inferring capital flow direction through price changes. When the stock price is rising, the transaction volume generated by active buy orders is the force driving the stock price up, which is defined as capital inflow. When the stock price is falling, the transaction volume generated by active sell orders is the force driving the stock price down, which is defined as capital outflow. The difference between the two on the same day is the net force remaining after offsetting the two forces, driving the stock price higher. The main fund flow, retail fund flow, and small investor fund flow are calculated based on transaction amounts of individual trades.
Note: Main funds refer to large orders, retail funds refer to medium and small orders, and small investor funds refer to small orders.
The above content is compiled by Securities Star based on publicly available information, generated by AI algorithms (Wangxin Algorithm Backup 310104345710301240019), and does not constitute investment advice.